Fundamental Analysis of Vertex Pharmaceuticals Inc - Growth / Value Index
VRTX - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.064
Tremendous increasing in Book Value last 3 year
Price to Book Ratio of 6.62 suggesting that it is very expensive
Valuation Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Price to Earning | 28.79 | 33.07 | -4.78 % | |
Price to Book | 6.87 | 6.53 | -21.29 % | 6.27 |
Price to Sales | 11.36 | 11.88 | -8.00 % | |
Enterprise Value to EBITDA Multiple | 24.66 | 28.42 | 20.11 % |
VRTX - Profitability Highlights
Profitability Analysis
Tsr Profitability Index - Good Score of 69.38
Excellent Net Margin for last 3 years
Excellent QoQ /QoQ FY EPS growth
Company Earning excess return
During the past twelve months, the company has given a strong Return On Equity of 21.69%
During the past twelve months, the company has given a strong Net Margin of 39.46%
All key Trailing Twelve Months Margin growing by 15 %
Annual Net Profit in last 3 years is trending up
Company's Net Profit is increasing for last 5 Quarters
Company's Profit Before Tax is increasing for last 5 Quarters
Steady Growth in EPS for last four quarters
Good Return On Capital Employed of 19.74
Very Low Dividend Yield of 0 %
Low Earning Yield of 3.61 %
Profitability Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Return On Equity | 21.69 | 19.74 | -17.34 % | 5.93 |
Return On Asset | 18.66 | 15.26 | -16.60 % | 4.60 |
Net Profit Margin | 39.46 | 35.94 | -3.38 % | 40.87 |
Operating Profit Margin | 41.60 | 45.67 | -5.30 % | 45.20 |
EBITDA Margin | 41.65 | 38.07 | -23.34 % | 42.35 |
Highlights
Market Cap | 114887 M |
Enterprise Value | 104602 M |
Price/Book TTM | 6.87 |
Outstanding Share | 258052 K |
Float/ Outstanding Share | 99.73% |
Dividend Yield | 0 % |
Share Holding
Guru Numbers
Price/Graham No | 2.89 |
Peter Lynch Ratio | 0.174 |
Piotroski F Score | 6.00 |
Altman Z Score | 15.50 |
Sloan Ratio | -0.0401 |
Peter Lynch Fair Value | 386.56 |
VRTX - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Quarterly sales in last 5 years is trending up
Steady increase in Total Assets for last 3 Years
Growth Key Fields
Field | TTM | YoY Growth | QoQ Growth |
---|---|---|---|
Revenue | 10185.00 M | 8.10 % | 6.87 % |
Gross Profit | 8852.10 M | 7.98 % | 9.46 % |
EBITDA | 4242.40 M | 17.13 % | 9.74 % |
Net Profit | 4019.40 M | 4.45 % | 13.50 % |
EPS | 15.46 | 5.02 % | NA |
VRTX - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 93.75
Altman Z Score of 15.00 suggests good Stability
Cash ratio of 3.16
Stability Key Ratios
Ratio | Latest FY | Yoy Change | MRQ |
---|---|---|---|
Debt to Equity Ratio | 0.0048 | -25.91 % | 0.0045 |
Cash Ratio | 3.16 | -28.67 % | |
Quick Ratio | 3.78 | -24.84 % | 3.29 |
Shareholders Equity | 77.34 | 0.905 % | |
Debt to EBITDA | 0.0228 | 12.98 % |
Historical Valuation Ratios of Vertex Pharmaceuticals Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Vertex Pharmaceuticals Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Vertex Pharmaceuticals Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Vertex Pharmaceuticals Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)